StockData
Harvard Bioscience Inc logo

Harvard Bioscience Inc (HBIO) stock

HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3040% above fair value
$9.08+0.17 (+1.91%)

Close on Nov 17, 2026Market cap $41.33MP/E –Yield –

Earnings

Harvard Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$22.20M
+7.8% on a year earlier
Diluted adjusted loss per share, Q3 FY2026
-$0.06
$0.00 a year earlier
Latest guidance
Lowered
Nov 10, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Harvard Bioscience's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open$22.20M+7.8%-$0.58-$0.06Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open$22.70M+10.7%-$0.64-$0.14Release
Q1 FY2026ended Mar 31, 2026May 12, 2026before the open$20.80M-4.6%-$0.77-$0.33Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026before the open$23.70M-3.7%-$0.06$0.00Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$20.60M-6.4%-$0.03$0.00Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025before the open$20.50M-11.3%-$0.05-$0.01Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open$21.80M-11.0%-$1.14-$0.01Release
Q4 FY2024ended Dec 31, 2024Mar 12, 2025before the open$24.60M-12.8%$0.00$0.06Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$22.00M-13.4%-$0.11-$0.02Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$23.10M-19.8%-$0.07$0.00Release
Q1 FY2024ended Mar 31, 2024May 7, 2024before the open$24.50M-18.3%-$0.11$0.02Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Harvard Bioscience's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueGAAPQ4 FY2026$23.70M – $25.50M–NewNov 10, 2026
Adjusted gross marginnon-GAAPQ4 FY202659% – 61%–NewNov 10, 2026
Adjusted EBITDAnon-GAAPQ4 FY2026$3.80M – $4.20M–NewNov 10, 2026
Revenue growthGAAPFY2026+3% – +5%–NewNov 10, 2026
Revenue growthFY2026+3% – +5%+2% – +4%RaisedAug 11, 2026
Revenue growthFY2026+2% – +4%–NewMar 12, 2026
Adjusted gross marginnon-GAAPFY202657% – 59%58% – 60%LoweredNov 10, 2026
Adjusted gross marginnon-GAAPFY202657% – 59%58% – 60%LoweredAug 11, 2026
Adjusted EBITDAnon-GAAPFY2026-1% – +4%+6% – +10%LoweredNov 10, 2026
Adjusted EBITDA growthnon-GAAPFY2026+6% – +10%+6% – +10%ReaffirmedAug 11, 2026

Guidance vs results

The last range Harvard Bioscience gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$21.00M – $22.60M$22.20MWithin range
Q2 FY2026Revenue$20.50M – $22.50M$22.70MAbove range
Q1 FY2026Revenue$20.00M – $22.00M$20.80MWithin range
Q4 FY2025Revenue$22.50M – $24.50M$23.70MWithin range
Q3 FY2025Revenue$19.00M – $21.00M$20.60MWithin range
Q2 FY2025Revenue$18.00M – $20.00M$20.50MAbove range
Q1 FY2025Revenue$19.00M – $21.00M$21.80MAbove range
Q4 FY2024Revenue$23.00M – $26.00M$24.60MWithin range
Q4 FY2022Revenue$30.00M$28.40MBelow range

Guidance history

Every forecast Harvard Bioscience put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026Adjusted EBITDAQ4 FY2026$3.80M – $4.20MNew
Nov 10, 2026Adjusted EBITDAFY2026-1% – +4%Lowered
Nov 10, 2026Adjusted gross marginQ4 FY202659% – 61%New
Nov 10, 2026Adjusted gross marginFY202657% – 59%Lowered
Nov 10, 2026RevenueQ4 FY2026$23.70M – $25.50MNew
Nov 10, 2026Revenue growthFY2026+3% – +5%New
Aug 11, 2026Adjusted EBITDA growthFY2026+6% – +10%Reaffirmed
Aug 11, 2026Adjusted EBITDAQ3 FY2026$1.50M – $2.50MNew
Aug 11, 2026Adjusted gross marginFY202657% – 59%Lowered
Aug 11, 2026Adjusted gross marginQ3 FY202656% – 58%New
Aug 11, 2026Revenue growthFY2026+3% – +5%Raised
Aug 11, 2026RevenueQ3 FY2026$21.00M – $22.60MNew
May 12, 2026Adjusted EBITDA growthFY2026+6% – +10%New
May 12, 2026Adjusted EBITDAQ2 FY2026$1.00M – $2.00MNew
May 12, 2026Adjusted gross marginFY202658% – 60%New
May 12, 2026Adjusted gross marginQ2 FY202657% – 59%New
May 12, 2026Revenue growthFY2026+2% – +4%New
May 12, 2026RevenueQ2 FY2026$20.50M – $22.50MNew
Mar 12, 2026Adjusted EBITDAQ1 FY2026$1.00M – $2.20MNew
Mar 12, 2026Adjusted EBITDA growthFY2026+6% – +10%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Harvard Bioscience filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. Update
  4. Results
  5. Update
  6. Results
  7. Update
  8. Results
  9. Update
  10. Results
  11. Update
  12. Update
  13. Results
  14. Update
  15. Results

See a number that looks wrong?